Aclarion, Inc.

NasdaqCM ACON

Aclarion, Inc. Shareholders' Equity for the quarter ending September 30, 2024

Aclarion, Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Aclarion, Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD -9.49 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: ACON

Aclarion, Inc.

CEO	Mr. Brent Ness
IPO Date	April 22, 2022
Location	United States
Headquarters	951 Mariners Island Boulevard
Employees	4
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Database Medical Instruments Pharmaceuticals Software-as-a-Service (SaaS) Telehealth

Description

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Key trends

Past 5 years